Literature DB >> 11354237

Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline.

W K Fakhoury1, D Wright, M Wallace.   

Abstract

The aims of this cross-sectional survey were to assess psychotic sufferers' perception of the effectiveness of their medication, the distress caused by adverse effects and the impact these might have on overall patient satisfaction with treatment. Three hundred and forty-one people diagnosed with psychosis who called a national mental health helpline (SANELINE) in the UK, between July 1998 and February 1999, were asked to take part in the survey. They were given a choice of either a postal questionnaire or a telephone interview in which the same questionnaire was used. One hundred and nineteen were interviewed on the telephone and 83 (out of 222) returned completed questionnaires. In total, information was available from 202 callers. Almost one-half of the respondents were dissatisfied with their medication, and almost all of them reported experiencing at least one adverse effect. Depression (or low mood), sedation and difficulty thinking and concentrating were the most prevalent adverse effects. Weight gain was the most distressing, particularly to women. Those taking atypical antipsychotics were significantly more likely than those on typical antipsychotics to experience insomnia and dry mouth, but were less likely to perceive depression and difficulty thinking/concentrating as quite or extremely distressing. Low satisfaction, as opposed to high satisfaction, was significantly associated with reporting weight gain, difficulty thinking/concentrating, insomnia and sexual dysfunction. It was also significantly associated with reporting weight gain, difficulty thinking/concentrating, muscle/joint stiffness and depression as quite or extremely distressing. Attention should be given to the management of cognitive impairment and weight gain as adverse effects of antipsychotics. Doctors should be more open to discussing the risks and nature of adverse effects with patients who should also be encouraged to do so.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11354237     DOI: 10.1097/00004850-200105000-00004

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  20 in total

Review 1.  Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis.

Authors:  Salvatore Gentile
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Frequency of Extrapyramidal Adverse Reactions in Schizophrenic Outpatients Treated with Risperidone, Olanzapine, Quetiapine or Haloperidol : Results of the EIRE Study.

Authors:  Julio Bobes; J Rejas; M Garcia-Garcia; F Rico-Villademoros; M P García-Portilla; M Madrigal; G Hernández
Journal:  Clin Drug Investig       Date:  2002-09       Impact factor: 2.859

Review 3.  Adverse effects of atypical antipsychotics : differential risk and clinical implications.

Authors:  Peter M Haddad; Sonu G Sharma
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 4.  Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life.

Authors:  Martin Lambert; Dieter Naber
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 5.  Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients.

Authors:  Alex J Mitchell; Davy Vancampfort; Amber De Herdt; Weiping Yu; Marc De Hert
Journal:  Schizophr Bull       Date:  2012-08-27       Impact factor: 9.306

6.  SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects.

Authors:  Peter M Haddad; W Wolfgang Fleischhacker; Joseph Peuskens; Roberto Cavallaro; Michael Ej Lean; Margarita Morozova; Gavin Reynolds; Jean-Michel Azorin; Pierre Thomas; Hans-Jürgen Möller
Journal:  Ther Adv Psychopharmacol       Date:  2014-02

7.  Development of the My Medicines and Me (M3Q) side effect questionnaire for mental health patients: a qualitative study.

Authors:  Deena M Ashoorian; Rowan M Davidson; Daniel J T Rock; Liza J Seubert; Rhonda M Clifford
Journal:  Ther Adv Psychopharmacol       Date:  2015-10

8.  Demographic and clinical correlates of sexual dysfunction among Nigerian male outpatients on conventional antipsychotic medications.

Authors:  Aina Kikelomo Oyekanmi; Adegoke Oloruntoba Adelufosi; Olukayode Abayomi; Timothy Olaolu Adebowale
Journal:  BMC Res Notes       Date:  2012-06-07

9.  Second generation antipsychotics improve sexual dysfunction in schizophrenia: a randomised controlled trial.

Authors:  Ahmed Mahmoud; Karen P Hayhurst; Richard J Drake; Shôn W Lewis
Journal:  Schizophr Res Treatment       Date:  2011-01-16

10.  Phentermine, sibutramine and affective disorders.

Authors:  Hoyoung An; Hyunjoo Sohn; Seockhoon Chung
Journal:  Clin Psychopharmacol Neurosci       Date:  2013-04-24       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.